BioLineRX (BLRX)

• Market cap: $14.7M
• 1 day: 3.68%
• 5 days: -0.59%
• 1 month: -2.87%
• 3 months: -7.9%
• 6 months: -35.86%
• Year to date: -66.93%
• 1 year: -66.73%
• 5 years: -96.4%
• 10 years: -99.61%
• Sector: Healthcare
• Industry: Biotechnology

About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Employees: 28